Clinical Trials | March 11, 2026
Roche reports Phase III persevERA breast cancer trial results
Giredestrant shows promise despite missing primary goal
Giredestrant shows promise despite missing primary goal
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
ShunzymeX leverages a proprietary protease to streamline purification
The facility is expected to become operational by FY2028-29
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
